Arylcyclohexylamine Derivatives: Pharmacokinetic, Pharmacodynamic, Clinical and Forensic Aspects
R. Pelletier, Brendan Le Daré, Diane Le Bouëdec, Angéline Kernalléguen, P. Ferron, Isabelle Morel, Thomas Gicquel
International Journal of Molecular Sciences December 1, 2022 DOI: 10.3390/ijms232415574 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The authors describe arylcyclohexylamine derivatives as an emerging class of new psychoactive substances whose recreational use is increasing and for which detailed toxicity data are lacking. They note that synthetic ketamine derivatives produced in Asia are arriving in Europe, where most are legal because they are not listed as narcotics, and that these derivatives can differ substantially from ketamine in pharmacokinetics and pharmacodynamics. |
Abstract
Since the 2000s, an increasing number of new psychoactive substances (NPS) have appeared on the drug market. Arylcyclohexylamine (ACH) compounds such as ketamine, phencyclidine and eticyclidine derivatives are of particular concern, given their rapidly increasing use and the absence of detailed toxicity data. First used mainly for their pharmacological properties in anesthesia, their recreational use is increasing. ACH derivatives have an antagonistic activity against the N-methyl-D-aspartate receptor, which leads to dissociative effects (dissociation of body and mind). Synthetic ketamine derivatives produced in Asia are now arriving in Europe, where most are not listed as narcotics and are, thus, legal. These structural derivatives have pharmacokinetic and pharmacodynamic properties that are sometimes very different from ketamine. Here, we describe the pharmacology, epidemiology, chemistry and metabolism of ACH derivatives, and we review the case reports on intoxication.
Citations in the library
Cited by 7
- The Resurgence of Hallucinogen Drugs in Clinical Research. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2023
- A combined toxicokinetic and metabolic approach to investigate deschloro-N-ethylketamine exposure in a multidrug user. Journal of Pharmaceutical and Biomedical Analysis June 15, 2024
- 3-Methoxy-Phencyclidine Induced Psychotic Disorder: A Literature Review and an 18F-FDG PET/CT Case Report. Pharmaceuticals March 31, 2024
- Emerging new psychoactive ketamine analogues: patterns of use and health risks identified by the French Addictovigilance Network. International Journal of Drug Policy July 1, 2026
- Rhabdomyolysis and Acute Kidney Injury after Use of 3-Methyl-PCP: A Case Report. Journal of Medical Toxicology April 1, 2026
and 2 more in the library
Cites 44
- Mechanisms of Ketamine Action as an Antidepressant Molecular Psychiatry March 13, 2018
- Ketamine use: a review Addiction July 21, 2011
- Ketamine: 50 Years of Modulating the Mind Frontiers in Human Neuroscience November 29, 2016
- Ketamine: NMDA Receptors and Beyond Journal of Neuroscience November 2, 2016
- From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis 2014
and 39 more in the library